SCHEMBL23345220

SCHEMBL23345220

CC(=O)N1CCC(O)(C(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
CYP2C19 P33261 3/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
USP2 O75604 3/20 0.36
OPRM1 P35372 2/20 0.36
OPRL1 P41146 2/20 0.36
HPGD P15428 1/20 0.36
CYP1A2 P05177 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP2D6 P10635 3/20 0.35
CYP2C9 P11712 1/20 0.35
CYP3A4 P08684 3/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23077821 0.88 CYP1A2 (0.43) CYP2C19ALDH1A1MAPK1USP2OPRM1
SCHEMBL350018 0.84 OPRM1 (0.38) CYP4F2CYP4A11CYP2C19ALDH1A1MAPK1
SCHEMBL23075986 0.83 SMN1; SMN2 (0.45) CYP4F2CYP4A11CYP2C19ALDH1A1MAPK1
SCHEMBL18069128 0.82 SMN1; SMN2 (0.42) CYP4F2CYP4A11CYP2C19ALDH1A1MAPK1
SCHEMBL25093263 0.77 USP2 (0.42) CYP2C19ALDH1A1MAPK1USP2HPGD
SCHEMBL23345238 0.74 SMN1; SMN2 (0.38) CYP2C19ALDH1A1MAPK1USP2OPRM1
SCHEMBL16888554 0.73 CYP1A2 (0.41) CYP2C19ALDH1A1MAPK1USP2HPGD
SCHEMBL18478135 0.72 SMN1; SMN2 (0.43) CYP2C19ALDH1A1MAPK1USP2HPGD
SCHEMBL14297361 0.72 SMN1; SMN2 (0.43) CYP2C19ALDH1A1MAPK1USP2HPGD
SCHEMBL23309174 0.72 CYP1A2 (0.44) CYP2C19ALDH1A1MAPK1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 CYP4F2 586/4885CYP4A11 305/4885CYP2C19 3214/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 CYP4F2 951/4885CYP4A11 696/4885CYP2C19 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.